InflaRx (IFRX) Competitors $1.84 -0.01 (-0.54%) Closing price 03:59 PM EasternExtended Trading$1.84 -0.01 (-0.27%) As of 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends IFRX vs. PROK, ABVX, ORGO, CMPX, AKBA, PRTC, ALT, CDXC, KMDA, and MREOShould you be buying InflaRx stock or one of its competitors? The main competitors of InflaRx include ProKidney (PROK), ABIVAX Société Anonyme (ABVX), Organogenesis (ORGO), Compass Therapeutics (CMPX), Akebia Therapeutics (AKBA), PureTech Health (PRTC), Altimmune (ALT), ChromaDex (CDXC), Kamada (KMDA), and Mereo BioPharma Group (MREO). These companies are all part of the "pharmaceutical products" industry. InflaRx vs. ProKidney ABIVAX Société Anonyme Organogenesis Compass Therapeutics Akebia Therapeutics PureTech Health Altimmune ChromaDex Kamada Mereo BioPharma Group ProKidney (NASDAQ:PROK) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations. Does the media favor PROK or IFRX? In the previous week, InflaRx had 3 more articles in the media than ProKidney. MarketBeat recorded 3 mentions for InflaRx and 0 mentions for ProKidney. InflaRx's average media sentiment score of 0.48 beat ProKidney's score of 0.00 indicating that InflaRx is being referred to more favorably in the news media. Company Overall Sentiment ProKidney Neutral InflaRx Neutral Do insiders and institutionals have more ownership in PROK or IFRX? 51.6% of ProKidney shares are held by institutional investors. Comparatively, 42.4% of InflaRx shares are held by institutional investors. 41.5% of ProKidney shares are held by company insiders. Comparatively, 16.3% of InflaRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts rate PROK or IFRX? ProKidney presently has a consensus price target of $4.50, indicating a potential upside of 200.00%. InflaRx has a consensus price target of $8.00, indicating a potential upside of 334.78%. Given InflaRx's stronger consensus rating and higher probable upside, analysts plainly believe InflaRx is more favorable than ProKidney.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProKidney 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40InflaRx 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation & earnings, PROK or IFRX? ProKidney has higher earnings, but lower revenue than InflaRx. ProKidney is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProKidneyN/AN/A-$35.47M-$0.55-2.73InflaRx$70K1,764.56-$46.18M-$1.08-1.70 Is PROK or IFRX more profitable? ProKidney has a net margin of 0.00% compared to InflaRx's net margin of -33,362.70%. ProKidney's return on equity of 0.00% beat InflaRx's return on equity.Company Net Margins Return on Equity Return on Assets ProKidneyN/A N/A -10.24% InflaRx -33,362.70%-65.98%-56.86% Does the MarketBeat Community prefer PROK or IFRX? InflaRx received 231 more outperform votes than ProKidney when rated by MarketBeat users. Likewise, 64.77% of users gave InflaRx an outperform vote while only 57.14% of users gave ProKidney an outperform vote. CompanyUnderperformOutperformProKidneyOutperform Votes857.14% Underperform Votes642.86% InflaRxOutperform Votes23964.77% Underperform Votes13035.23% Which has more risk & volatility, PROK or IFRX? ProKidney has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Comparatively, InflaRx has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500. SummaryInflaRx beats ProKidney on 9 of the 17 factors compared between the two stocks. Get InflaRx News Delivered to You Automatically Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IFRX vs. The Competition Export to ExcelMetricInflaRxPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$123.52M$7.04B$5.78B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-1.706.1326.4618.82Price / Sales1,764.56313.46457.9780.74Price / CashN/A67.8344.0437.47Price / Book0.976.747.634.64Net Income-$46.18M$138.11M$3.18B$245.69M7 Day Performance-8.00%-2.02%-1.82%-2.63%1 Month Performance-25.51%-1.54%0.22%-2.37%1 Year Performance21.85%-3.14%17.49%13.65% InflaRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IFRXInflaRx3.292 of 5 stars$1.84-0.5%$8.00+334.8%+20.9%$123.52M$70,000.00-1.7060PROKProKidney1.3484 of 5 stars$1.61+0.6%$4.50+179.5%+1.3%$469.57MN/A-2.933ABVXABIVAX Société Anonyme2.0226 of 5 stars$7.40+3.2%$38.67+422.5%-37.5%$468.94MN/A0.0061News CoverageORGOOrganogenesis3.9608 of 5 stars$3.70+0.5%$5.00+35.1%-1.2%$465.20M$433.14M-61.67950News CoverageCMPXCompass Therapeutics3.3152 of 5 stars$3.38-2.0%$11.17+230.4%+67.3%$465.05M$850,000.00-9.1320Analyst ForecastAKBAAkebia Therapeutics4.0776 of 5 stars$2.13-0.5%$7.50+252.1%+32.3%$464.72M$194.62M-9.26430Analyst DowngradePRTCPureTech Health2.1576 of 5 stars$18.95flat$45.00+137.5%-29.4%$453.66M$3.33M0.00100ALTAltimmune2.6073 of 5 stars$6.37+2.2%$20.83+227.1%-21.1%$453.03M$430,000.00-4.1150Short Interest ↓CDXCChromaDex4.4664 of 5 stars$5.87+5.2%$8.00+36.3%+258.5%$448.35M$83.57M587.59120News CoverageKMDAKamada4.0397 of 5 stars$7.78-2.1%$14.50+86.4%+26.0%$447.19M$142.52M27.79360High Trading VolumeMREOMereo BioPharma Group2.8997 of 5 stars$2.87-0.3%$7.83+172.9%-19.8%$445.28M$10M0.0040 Related Companies and Tools Related Companies ProKidney Competitors ABIVAX Société Anonyme Competitors Organogenesis Competitors Compass Therapeutics Competitors Akebia Therapeutics Competitors PureTech Health Competitors Altimmune Competitors ChromaDex Competitors Kamada Competitors Mereo BioPharma Group Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IFRX) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InflaRx Please log in to your account or sign up in order to add this asset to your watchlist. Share InflaRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
